Abstract
During the last 20 years, treatment paradigms as well as drugs used for IBD have changed significantly. However, there are still many unmet needs and a significant number of patients needing better therapy. It is obvious from this situation that many attempts have been made to implement new drugs and treatment algorithms including biologicals, new formulations of old drugs and ‘fancy molecules or approaches'. For about 10 years, the application of Trichuris suis ova has been promoted and used in quite a number of patients. Two early studies suggested positive effects in ulcerative colitis as well as in Crohn's disease. These studies were based on experimental data in animal models as well as in vitro experiments. However, two large randomized controlled trials were not able to provide significant clinical effects in active Crohn's disease as compared to placebo, although a biological reaction (eosinophilia) was found. Another approach is the use of locally released phosphatidylcholine in ulcerative colitis. This approach is based on decreased phosphatidylcholine concentrations in the colonic mucus in patients, and showed positive effects in a number of monocentric trials in steroid-refractory and chronic active ulcerative colitis. A dose-finding study gave a positive signal in the highest-dose group and this approach is being tested further in controlled trials. Many other ‘fancy molecules' including cannabis, vitamin D, thalidomide, hyaluronic acid, lidocaine, clonidine, chondroitin sulfate, naltrexone and melatonin have been tested in patients with claims of success. For most of those, however, controlled data in appropriate studies are lacking. Many more substances have been used in animal models and are probably applied in individual patients. Results of preliminary studies on some of the molecules mentioned are presented.
Journal Section:
New Therapies or New Therapeutic Strategies in IBD?
References
1.
Danese S: New therapies for inflammatory bowel disease: from the bench to the bedside. Gut 2012;61:918-932.
[PubMed]
2.
Scharl M, Vavricka SR, Rogler G: Review: new anti-cytokines for IBD: what is in the pipeline? Curr Drug Targets 2013;14:1405-1420.
[PubMed]
3.
Rook GA: Hygiene and other early childhood influences on the subsequent function of the immune system. Dig Dis 2011;29:144-153.
[PubMed]
4.
Elliott DE, Weinstock JV: Helminth-host immunological interactions: prevention and control of immune-mediated diseases. Ann NY Acad Sci 2012;1247:83-96.
[PubMed]
5.
Elliott DE, Weinstock JV: Where are we on worms? Curr Opin Gastroenterol 2012;28:551-556.
[PubMed]
6.
Walk ST, Blum AM, Ewing SA, Weinstock JV, Young VB: Alteration of the murine gut microbiota during infection with the parasitic helminth Heligmosomoides polygyrus. Inflamm Bowel Dis 2010;16:1841-1849.
[PubMed]
7.
Cançado GG, Fiuza JA, de Paiva NC, et al: Hookworm products ameliorate dextran sodium sulfate-induced colitis in BALB/c mice. Inflamm Bowel Dis 2011;17:2275-2286.
[PubMed]
8.
Hunter MM, Wang A, Hirota CL, McKay DM: Neutralizing anti-IL-10 antibody blocks the protective effect of tapeworm infection in a murine model of chemically induced colitis. J Immunol 2005;174:7368-7375.
[PubMed]
9.
Elliott DE, Setiawan T, Metwali A, Blum A, Urban JF Jr, Weinstock JV: Heligmosomoides polygyrus inhibits established colitis in IL-I0-deficient mice. Eur J Immunol 2004;34:2690-2698.
[PubMed]
10.
Schnoeller C, Rausch S, Pillai S, Avagyan A, Wittig BM, Loddenkemper C, Hamann A, Hamelmann E, Lucius R, Hartmann S: A helminth immunomodulator reduces allergic and inflammatory responses by induction of IL-I0-producing macrophages. J Immunol 2008;180:4265-4272.
[PubMed]
11.
Hang L, Setiawan T, Blum AM, Urban J, Stoyanoff K, Arihiro S, Reinecker HC, Weinstock JV: Heligmosomoides polygyrus infection can inhibit colitis, through direct interaction with innate immunity. J Immunol 2010;185:3184-3189.
[PubMed]
12.
Broadhurst MJ, Leung JM, Kashyap V, McCune JM, Mahadevan U, McKerrow JH, Loke P: IL-22+ CD4+ T ceIIs are associated with therapeutic Trichuris trichiura infection in an uIcerative colitis patient. Sci Transl Med 2010;2:60ra88.
[PubMed]
13.
Summers RW, Elliott DE, Urban JF Jr, Thompson R, Weinstock JV: Trichuris suis therapy in Crohn's disease. Gut 2005;54:87-90.
[PubMed]
14.
Summers RW, Elliott DE, Urban JF Jr, Thompson RA, Weinstock JV: Trichuris suis therapy for active ulcerative colitis: a randomized controIIed trial. Gastroenterology 2005;128:825-832.
[PubMed]
15.
Braun A, Treede I, Gotthardt D, Tietje A, Zahn A, Ruhwald R, Schoenfeld U, Welsch T, Kienle P, Erben G, Lehmann WD, Fuellekrug J, Stremmel W, Ehehalt R: Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: a clue to pathogenesis. Inflamm Bowel Dis 2009;15:1705-1720.
[PubMed]
16.
Treede I, Braun A, Sparla R, Kühnel M, Giese T, Turner JR, Anes E, Kulasksiz H, Füllekrug J, Stremmel W, Griffiths G, Ehehalt R: Anti-inflammatory effects of phosphatidylcholine. J Biol Chem 2007;282:27155-22764.
[PubMed]
17.
Stremmel W, Merle U, Zahn A, Autschbach F, Hinz U, Ehehalt R: Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. Gut 2005;54:966-971.
[PubMed]
18.
Stremmel W, Ehehalt R, Autschbach F, Karner M: Phosphatidylcholine for steroid-refractory chronic ulcerative colitis: a randomized trial. Ann Intern Med 2007;147:603-610.
[PubMed]
19.
Karner M, Schmieg V, Hanemann A, Zahn A, Braun A, Karner H, Merle U, Ehehalt R, Stremmel W: Results of a long term follow up treatment with delayed release phosphatidylcholine in chronic-active ulcerative colitis. Gastroenterology 2008;134:A493.
20.
Stremmel W, Hanemann A, Braun A, Stoffels S, Karner M, Fazeli S, Ehehalt R: Delayed release phosphatidylcholine as new therapeutic drug for ulcerative colitis: a review of three clinical trials. Expert Opin Investig Drugs 2010;19:1623-1630.
[PubMed]
21.
Karner M, Kocjan A, Stein J, Schreiber S, von Boyen G, Uebel P, Schmidt C, Kupcinskas L, Dina I, Zuelch F, Keilhauer G, Stremmel W: First multicenter study of modified release phosphatidylcholine ‘LT-02' in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses. Am J Gastroenterol 2014;109:1041-1051.
[PubMed]
22.
Inagaki T, Moschetta A, Lee YK, Peng L, Zhao G, Downes M, Yu RT, Shelton JM, Richardson JA, Repa JJ, Mangelsdorf DJ, Kliewer SA: Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci USA 2006 7;103:3920-3925.
[PubMed]
23.
Gadaleta RM, van Erpecum KJ, Oldenburg B, et al: Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 2011;60:463-472.
[PubMed]
24.
Vavassori P, Mencarelli A, Renga B, Distrutti E, Fiorucci S: The bile acid receptor FXR is a modulator of intestinal innate immunity. J Immunol 2009 15;183:6251-6261.
[PubMed]
25.
Desreumaux P, Dubuquoy L, Nutten S, et al: Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J Exp Med 2001;193:827-838.
[PubMed]
26.
Su CG, Wen X, Bailey ST, Jiang W, Rangwala SM, Keilbaugh SA, Flanigan A, Murthy S, Lazar MA, Wu GD: A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 1999;104:383-389.
[PubMed]
27.
Lewis JD, Lichtenstein GR, Stein RB, Deren JJ, Judge TA, Fogt F, Furth EE, Demissie EJ, Hurd LB, Su CG, Keilbaugh SA, Lazar MA, Wu GD: An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis. Am J Gastroenterol 2001;96:3323-3328.
[PubMed]
28.
Lewis JD, Lichtenstein GR, Deren JJ, Sands BE, Hanauer SB, Katz JA, Lashner B, Present DH, Chuai S, Ellenberg JH, Nessel L, Wu GD; Rosiglitazone for Ulcerative Colitis Study Group: Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology 2008;134:688-695.
[PubMed]
29.
Vetrano S, Genua M, Petti L, Naccarato P, Gandelli A, Tacconi C, Arena V, D'Alessio S, Danese S: IBD98E promotes mucosal wound healing through epithelial cell proliferation in DSS-induced colitis. J Crohns Colitis 2014;8:S90-S91.
30.
Fiorino G, Gilardi D, Naccarato P, Sociale OR, Danese S: Safety and efficacy of sodium hyaluronate (IBD98E) in the induction of clinical and endoscopic remission in subjects with distal ulcerative colitis. Dig Liver Dis 2014;46:330-334.
[PubMed]
31.
Linares PM, Chaparro M, Algaba A, Guerra I, Román M, Moreno Arza I, Abad Santos F, Ochoa D, Bermejo F, Gisbert JP: Effect of chondroitin sulphate on pro-inflammatory mediators and disease activity in patients with inflammatory bowel disease (IBD). J Crohns Colitis 2014;8:S95.
32.
Lechin F, van der Dijs B, Insausti CL, Gómez F, Villa S, Lechin AE, Arocha L, Oramas O: Treatment of ulcerative colitis with clonidine. J Clin Pharmacol 1985;25:219-222.
[PubMed]
33.
Saibil FG: Lidocaine enemas for intractable distal ulcerative colitis (IDUC): efficacy and safety. Gastroenterology 1998;114:A1073.
34.
Massa F, Marsicano G, Hermann H, Cannich A, Monory K, Cravatt BF, Ferri GL, Sibaev A, Storr M, Lutz B: The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 2004;113:1202-1209.
[PubMed]
35.
Naftali T, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F, Konikoff FM: Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. Clin Gastroenterol Hepatol 2013;11:1276-1280.
[PubMed]
36.
Jørgensen SP, Agnholt J, Glerup H, Lyhne S, Villadsen GE, Hvas CL, Bartels LE, Kelsen J, Christensen LA, Dahlerup JF: Clinical trial: vitamin D3 treatment in Crohn's disease - a randomized double-blind placebo-controlled study. Aliment Pharmacol Ther 2010;32:377-383.
[PubMed]
37.
Lie MR, Fuhler F, de Lima A, van der Ent C, van der Woude CJ: Low dose naltrexone in therapy resistant IBD, a case series. Gastroenterology 2014;146:A464.
38.
Andus T, Klebl F, Rogler G, Bregenzer N, Schölmerich J, Straub RH: Patients with refractory Crohn's disease or ulcerative colitis respond to dehydroepiandrosterone: a pilot study. Aliment Pharmacol Ther 2003;17:409-414.
[PubMed]
39.
Lazzerini M, Martelossi S, Magazzù G, et al: Effect of thalidomide on clinical remission in children and adolescents with refractory Crohn disease: a randomized clinical trial. JAMA 2013;310:2164-2173.
[PubMed]
40.
Hanai H, Iida T, Takeuchi K, et al: Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006;4:1502-1506.
[PubMed]
41.
Singla V, Pratap Mouli V, Garg SK, Rai T, Choudhury BN, Verma P, Deb R, Tiwari V, Rohatgi S, Dhingra R, Kedia S, Sharma PK, Makharia G, Ahuja V: Induction with NCB-02 (curcumin) enema for mild-to-moderate distal ulcerative colitis - a randomized, placebo-controlled, pilot study. J Crohns Colitis 2014;8:208-214.
[PubMed]
42.
Langmead L, Feakins RM, Goldthorpe S, Holt H, Tsironi E, De Silva A, Jewell DP, Rampton DS: Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. Aliment Pharmacol Ther 2004;19:739-747.
[PubMed]
43.
Sandborn WJ, Targan SR, Byers VS, Rutty DA, Mu H, Zhang X, Tang T: Andrographis paniculata extract (HMPL-004) for active ulcerative colitis. Am J Gastroenterol 2013;108:90-98.
[PubMed]
44.
Biedermann L, Mwinyi J, Scharl M, Frei P, Zeitz J, Kullak-Ublick GA, Vavricka SR, Fried M, Weber A, Humpf HU, Peschke S, Jetter A, Krammer G, Rogler G: Bilberry ingestion improves disease activity in mild to moderate ulcerative colitis - an open pilot study. J Crohns Colitis 2013;7:271-279.
[PubMed]
45.
Langmead L, Rampton DS: Review article: complementary and alternative therapies for inflammatory bowel disease. Aliment Pharmacol Ther 2006;23:341-349.
[PubMed]
46.
Gilardi D, Fiorino G, Genua M, Allocca M, Danese S: Complementary and alternative medicine in inflammatory bowel disease: what is the future in the field of herbal medicine. Expert Rev Gastroenterol Hepatol 2014;12:1-12.
[PubMed]
47.
Torres J, Danese S, Colombel JF: New therapeutic avenues in ulcerative colitis. Gut 2013;62:1642-1652.
[PubMed]
© 2014 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2014
You do not currently have access to this content.
